Press Release FeedGet the RSS feed
Menu

Business Wire

NFL Biosciences Reports Its 2026 Half-Year Results and Progress With Its Two Immunotherapies for Smoking and Nicotine Cessation

Business Wire

  • NFL-101 – immunotherapy aimed at reducing neuroinflammation:

    • Biomarker results supporting a personalized medicine approach

    • Next step: discussions with the FDA and EMA to confirm the Phase 3 clinical development plan

  • NFL-102 – immunotherapy aimed at restoring neuroplasticity

    • Successful manufacturing of a GMP-compliant clinical batch

    • Obtaining regulatory approvals to begin the TONIC Phase 2 trial

    • Launch of the TONIC study, consisting of Part A (the first 40 participants) and Part B (the next 270 participants), scheduled for November 2026

  • Positive initial results from the study conducted at McLean Hospital / Harvard Medical School on the effects of NFL Biosciences' immunotherapies on neurotransmitters

  • Intellectual property portfolio expanded to five patent families, including two new applications filed in the first half of the year

  • Cash position of €2.5 million as of June 30, 2026, and cash runway through the end of the first half of 2027, including funding for Part A of the TONIC study

MONTPELLIER, France, October 22, 2026--Regulatory News:

NFL Biosciences (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing immunotherapies for smoking and nicotine cessation, announces its financial results for the first half of 2026, as approved by the Board of Directors on October 22, 2026, and provides an update on progress with its two programs.

NFL Biosciences aims to broaden the therapeutic options available to smokers wishing to quit by developing approaches not yet available in smoking cessation: immunotherapy and patient selection using a biomarker predictive of response. These two approaches, which have profoundly transformed cancer treatment, are central to the development of NFL-101 and NFL-102.

Bruno Lafont, Chief Executive Officer and co-founder of NFL Biosciences, states: "Tobacco is the leading preventable cause of cancer worldwide. Yet, while oncology benefits from immunotherapies and treatments guided by predictive biomarkers, smoking cessation drugs remain focused on nicotinic receptors. Our ambition is to bring the treatment of tobacco dependence into this new therapeutic era. With NFL-101 and NFL-102, we are developing two distinct immunotherapies, including a personalized approach aimed at identifying the smokers most likely to respond to treatment. The progress achieved brings us closer to this goal. "

NFL Biosciences has completed several previously announced milestones: manufacturing and quality control of the NFL-102 clinical batch, obtaining regulatory approvals to begin the Phase 2 trial, and presentation of scientific results at the scheduled conferences.

  1. FinanceCushman & WakefieldCushman & Wakefield Strengthens Chicago Office Leasing and Capital Markets Teams with Addition of Peter Adamo, Adam Lawler and Madeline LelandAdam Lawler Trio brings extensive experience advising owners and investors across Chicago's suburban office market and will provide leasing and capital markets advisory services CHICAGO, October 22, 2026--Cushman & Wakefield (NYSE: CWK), a leading global real estate services firm, today announced the a
  2. EducationThe Connellsville Area School DistrictConnellsville Area School District Kicks Off Major Infrastructure Modernization Project at District’s Largest Elementary SchoolConnellsville Area School District marks the start of a major modernization of Dunbar Township Elementary School, including a new community-championed inclusive playground designed to create greater opportunities for students of all abilities to play and connect. The comprehensive project represents the first major renova
  3. ComEd, Metropolitan Mayors Caucus Help Make Spirits Bright this Season with 28 Grants to Power Holiday Light EventsSixth annual Powering the Holidays Grant Program provides $69,500 to support decoration and lighting projects in northern Illinois communities CHICAGO, October 22, 2026--With the holiday season just around the corner, ComEd and the Metropolitan Mayors Caucus are brightening communities across northern
  4. InsuranceAM Best Maintains Under Review With Negative Implications Status for Bao Minh Insurance CorporationSINGAPORE, October 22, 2026--AM Best has maintained the under review with negative implications status for the Financial Strength Rating of B++ (Good), the Long-Term Issuer Credit Rating of "bbb" (Good) and the Vietnam National Scale Rating of aaa.VN (Exceptional) of Bao Minh Insurance Corporation (BM
  5. EnergyCore Development GroupCore Development Group Marks 15-Year Anniversary as a National Leader in Energy SolutionsNJ-based energy contractor is driving the future of clean energy infrastructure across the U.S. MAHWAH, N.J., October 22, 2026--Core Development Group , a leading energy Engineering, Procurement, and Construction (EPC) contractor, celebrates 15 years in business and a strong history of constructing re
  6. EducationPacific CollegePacific College Taps Physician and Healthcare Leader Dr. Ramin Baschshi to Guide Its Next ChapterNew President Pairs 25+ Years in Medicine and Nonprofit Leadership With a People-First Approach to Preparing California's Next Generation of Nurses COSTA MESA, Calif., October 22, 2026--Pacific College , a Southern California nursing school that has prepared healthcare professionals since 1993, today